Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks?

Every January, Johnson & Johnson (NYSE: JNJ) executives share their expectations for the year ahead, and this year investors didn't like what they heard. The company isn't expecting much growth from its pharmaceutical segment in 2019, or next year.